Clinical Professor of Medicine Moores UCSD Cancer Center
Oncology
Dr. Frederick E. Millard, MD
|
|
Give Review
Dr. Frederick E. Millard works in the field of Oncology. He researched medicine at Jefferson Medical College. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Frederick Millard is also a published MD. He has 18 paper published. The most recent paper is: Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival ... Frederick Millard accepts all Medicare patients.
Publications
- Molecular aberrations, targeted therapy, and renal Cell carcinoma: current state-of-the-art.
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate Cancer: Resu...
- Target localization and toxicity in dose-escalated proState radiotherapy with image-guided approach using daily planar kilovoltage imaging.
- Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional Study.
- Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
- Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate Cancer.
- Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
- Prostate bed localization with image-guided approach using on-board imaging: reporting Acute toxicity and implications for radiation therapy planning following prostat...
- Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional Cell carcinoma: CALGB 90207.
- A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian Cancer patients: CALGB 9871.
- Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
- Palliative irradiation of the spleen.
- What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative Disorders?
- Update on chemotherapy in the treatment of urothelial Carcinoma.
- Immunogenic HLA-B7-restricted peptides of hTRT.
- Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: Analysis of survival ...
- A specific assay for anti-HLA antibodies: application to platelet donor selection.
Schools
Jefferson Medical College Of Thomas Jefferson University Thomas Jefferson University
Naval Med Center
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Power Select HMO
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Federal Employee Program (FEP)
- First Health (Coventry Health Care) PPO
- GEHA
- Medicare Advantage PFFS
- HealthSmart
- Humana
- Kaiser Permanente
- Medicaid
- Medicare MCR
- Molina
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- National Elevator
- Principal Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
- Worker's Compensation WC
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Naval Medical Center -
Jefferson Medical College
Hospital
-
UC San Diego Health
Drug Facts
| NPI NUMBER | 1922056373 | |
| NPPES Provider LastName | MILLARD | |
| NPPES Provider FirstName | FREDERICK | |
| NPPES Provider ZIPCode | 920930987 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1065.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 115.0 | |
| Percent Opioid Claims | 10.8 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1922056373 |
| Last Name Of The Provider | MILLARD |
| First Name Of The Provider | FREDERICK |
| View All |
Similar Doctors
|
|
Dr. Michel B. Choueiri, MD |
|
|
Dr. Peter T. Curtin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah G. Boles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory A. Daniels, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marie P. Shieh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Huan-You Wang, MD |
|
|
Dr. Carolyn M. Mulroney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa L. Helsten, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward Kavalerchik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James M. Randall Jr., MD
This Doctor is OpenDoctor Recommended.
|